Internetové knihkupectví s veterinární tématikou

Detail zboží

Veterinary Psychopharmacology, 2nd Edition

Stručný popis

Zcela revidované druhé vydání nabízí informace o terapii psychiatrických, psychologických a behaviorálních poruch u domácích mazlíčků. Jako přístupný zdroj je text rozdělen do sekcí o psychofarmakologických principech a klinické psychofarmakologii. Obsahuje podrobné informace o farmakologickém zásahu v oblasti duševního zdraví a chování domácích zvířat. Poskytuje důkladné vysvětlení možností a navrhuje, jaká léčiva by měla být předepsána a jak fungují. Aktualizované vydání zahrnovalo nejnovější poznatky v psychofarmakologii pro domácí zvířata. Zahrnuje nové kapitoly, které se týkají principů psychofarmakologie, různých serotonergních látek, antikonvulziv a stabilizátorů nálad, sympatolytických látek a antagonistů NMDA. Text vysvětluje možnosti léku, včetně všech informací nezbytných k nápravě dysfunkcí chemie mozku pomocí farmakologické léčby. Tento důležitý zdroj představuje aktualizovaný a komplexní zdroj pro farmakologické léčení psychiatrických poruch zvířat, koní a zoozvířat a poruch chování. Obsahuje podrobné informace o lécích, které podporují neurochemické změny, které změní náladu, emoční stav, reaktivitu a chování pacienta, včetně možností předepisování a mechanismů účinku. Zahrnuje nové kapitoly o zásadách psychofarmakologie, různých serotonergních látkách, stabilizátorech nálady, sympatolytických látkách a antagonisty NMDA.


Autor: Sharon L. Crowell-Davis, DVM, PhD, DACVB, is a Professor of Behavioral Medicine in the Department of Veterinary Biosciences and Diagnostic Imaging, College of Veterinary Medicine, the University of Georgia in Athens, Georgia, USA. Thomas F. Murray, PhD, is a Professor of Pharmacology and Provost of Creighton University in Omaha, Nebraska, USA. Leticia Mattos de Souza Dantas, DVM, MS, PhD, DACVB is a Clinical Assistant Professor of Behavioral Medicine at the University of Georgia Veterinary Teaching Hospital and the Department of Veterinary Biosciences and Diagnostic Imaging at the College of Veterinary Medicine, University of Georgia in Athens, Georgia, USA. She is also the Director and Co-founder of ZooPsych, Inc., a consultancy in Clinical Behavioral Medicine & Therapy in Georgia, USA.

Cena s DPH:  2869 Kč
Skladem méně než 5 kusů
Zboží máme skladem!
Základní informace
NakladatelWiley-Blackwell
ISBN9781119226222
VydáníII. vydání 2019
Vazba
Počet stran336
Popis

Offers an updated second edition of the comprehensive reference on the use of drugs for veterinary mental health care and behavior modification

This fully revised Second Edition of Veterinary Psychopharmacology offers an authoritative reference to the drugs prescribed to treat psychiatric, psychological, and behavioral disorders in pets. Designed to be an accessible resource, the text is divided into sections on psychopharmacologic principles and clinical psychopharmacology. Comprehensive in scope, the book contains detailed information on pharmacologic intervention for pet mental health and behavior issues, offers thorough explanations of options, and explores why a particular drug should be prescribed and why it works.

Updated to include the recent advances in psychopharmacology for pets, the Second Edition includes new chapters that cover the principles of psychopharmacology, miscellaneous serotonergic agents, anticonvulsants and mood stabilizers, sympatholytic agents, and NMDA antagonists. In addition, the text explains the drug options, including all the information necessary to correct dysfunctions in the brain’s chemistry through pharmacologic treatment. This important resource:

• Presents an updated and comprehensive resource for pharmacologic treatments for pet, equine, and zoo animal psychiatric disorders and behavior problems

• Contains in-depth information on drugs that promote neurochemical changes that will alter the mood, emotional state, reactivity, and behavior of the patient, including prescribing options and mechanisms of action

• Includes new chapters on the principles of psychopharmacology, miscellaneous serotonergic agents, mood stabilizers, sympatholytic agents, and NMDA antagonists

Written for veterinarians, veterinary behaviorists, and veterinary students, the updated second edition of Veterinary Psychopharmacology is a complete source for current knowledge on pharmacologic behavior modification.

Obsah
Contributors xxi
Prefacexxiii
Acknowledgmentsxxv
Part I Principles of Veterinary Psychopharmacology1
1 General Principles of Psychopharmacology3
Thomas F. Murray Drug Action3
Dose Dependence of Drug Interaction with Receptors4
Structural Features of the Central Nervous System (CNS) and Neurotransmission5
Biogenic Amine Neurotransmitters and Affective Disorders8
2 Amino Acid Neurotransmitters: Glutamate, GABA, and the Pharmacology of Benzodiazepines11
Thomas F. Murray Introduction11
Glutamatergic Synapses11
Pharmacology of Ketamine and Tiletamine14
GABAergic Synapses15
3 Biogenic Amine Neurotransmitters: Serotonin21
Thomas F. Murray Introduction21
The Biogenic Amines21
Serotonin22
4 Biogenic Amine Transmitters: Acetylcholine, Norepinephrine, and Dopamine29
Thomas F. Murray Acetylcholine29
Norepinephrine32
Dopamine37
5 Neuropeptides: Opioids and Oxytocin43
Thomas F. Murray Introduction43
Endogenous Opioid Peptides43
Oxytocin47
Part II Practice of Veterinary Psychopharmacology51
6 Introduction to Clinical Psychopharmacology for Veterinary Medicine53
Sharon L. Crowell‐Davis and Leticia Mattos de Souza Dantas Introduction53
Prescribing in the United States: The Animal Medicinal Drug Use Clarification Act (AMDUCA 1994)54
Cost55
Drug Selection56
Medicating the Patient57
Competition Animals58
Taking the Behavioral History58
The Behavioral Exam63
Duration of Treatment63
Limitations64
7 Benzodiazepines67
Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis Action67
Overview of Indications67
Contraindications, Side Effects, and Adverse Events69
Overdose69
Clinical Guidelines69
Specific Medications71
I. Alprazolam71
II. Chlordiazepoxide HC173
IV. Clorazepate Dipotassium78
V. Diazepam80
VI. Flurazepam Hydrochloride86
VII. Lorazepam87
VIII. Oxazepam89
IX. Triazolam91
8 Selective Serotonin Reuptake Inhibitors103
Niwako Ogata, Leticia Mattos de Souza Dantas, and Sharon L. Crowell‐Davis Action103
Overview of Indications103
Contraindications, Side Effects, and Adverse Events104
Adverse Drug Interactions104
Overdose105
Clinical Guidelines105
Specific Medications106
I. Citalopram Hydrobromide106
II. Fluoxetine Hydrochloride108
III. Fluvoxamine115
IV. Paroxetine Hydrochloride117
V. Sertraline Hydrochloride119
VI. Escitalopram Oxalate122
9 Miscellaneous Serotonergic Agents129
Leticia Mattos de Souza Dantas and Sharon L. Crowell‐Davis Introduction129
Azapirones129
Action129
Overview of Indications129
Contraindications, Side Effects, and Adverse Events129
Adverse Drug Interactions129
Overdose129
Clinical Guidelines129
Specific Medications130
I. Buspirone130
I. Trazodone Hydrochloride135
10 Anticonvulsants and Mood Stabilizers147
Sharon L. Crowell‐Davis, Mami Irimajiri, and Leticia Mattos de Souza Dantas Action147
Overview of Indications148
Clinical Guidelines148
Specific Medications148
I. Carbamazepine148
II. Gabapentin149
III. Pregabalin152
11 Sympatholytic Agents157
Niwako Ogata and Leticia Mattos de Souza Dantas Action157
Overview of Indications157
Contraindications, Side Effects, and Adverse Events158
Overdose159
Clinical Guidelines159
Specific Medications160
I. Clonidine160
II. Detomidine161
III. Dexmedetomidine163
IV. Propranolol165
12 N‐Methyl‐D‐Aspartate (NMDA) Receptor Antagonists171
Niwako Ogata and Leticia Mattos de Souza Dantas Action171
Overview of Indications172
Contraindications/ Side Effects, and Adverse Events172
Clinical Guidelines173
Specific Medications173
I. Dextromethorphan173
II. Amantadine175
III. Memantine176
IV. Huperzine A179
13 Monoamine Oxidase Inhibitors185
Leticia Mattos de Souza Dantas and Sharon L. Crowell‐Davis Action185
Overview of Indications186
Specific Medications186
I. Selegiline Hydrochloride186
14 Antipsychotics201
Lynne Seibert and Sharon Crowell‐Davis Introduction201
Action201
Overview of Indications202
General Pharmacokinetics203
Contraindications, Side Effects, and Adverse Events203
Overdose203
Clinical Guidelines204
Specific Medications204
I. Acepromazine Maleate204
II. Azaperone206
III. Chlorpromazine206
IV. Clozapine207
V. Fluphenazine208
VI. Haloperidol209
VII. Pimozide210
VIII. Promazine211
IX. Sulpiride211
X. Thioridazine212
15 CNS Stimulants217
Sharon L. Crowell‐Davis Action217
Overview of Indications217
Contraindications, Side Effects, and Adverse Events217
Adverse Drug Interactions217
Overdose217
Clinical Guidelines218
Specific Medications219
I. Amphetamine219
II. Atomoxetine HCl221
III. Methylphenidate Hydrochloride223
16 Tricyclic Antidepressants231
Sharon L. Crowell‐Davis Action231
Overview of Indications231
Contraindications, Side Effects, and Adverse Events232
Adverse Drug Interactions232
Overdose232
Discontinuation233
Clinical Guidelines233
Specific Medications233
I. Amitriptyline233
II. Clomipramine Hydrochloride236
III. Desipramine243
IV. Doxepin244
V. Imipramine246
VI. Nortriptyline248
17 Opioids and Opioid Antagonists257
Leticia Mattos de Souza Dantas and Sharon L. Crowell‐Davis Action257
Overview of Indications257
Contraindications, Side Effects, and Adverse Events258
Clinical Guidelines258
Specific Medications258
I. Nalmefene258
II. Naloxone HCl260
III. Naltrexone Hydrochloride261
IV. Pentazocine264
18 Hormones269
Sharon L. Crowell‐Davis Introduction269
Oxytocin270
Clinical Pharmacology270
Indications270
Side Effects270
Doses in Nonhuman Animals270
Effects Documented in Nonhuman Animals270
Progestins270
Action270
Overview of Indications271
Contraindications, Side Effects, and Adverse Events271
Overdose271
Clinical Guidelines272
Specific Medications272
I. Medroxyprogesterone Acetate (MPA)272
II. Megestrol Acetate273
19 Combinations281
Leticia Mattos de Souza Dantas, Sharon L. Crowell‐Davis, and Niwako Ogata Introduction281
Overview of Drug Augmentation281
Potentially Beneficial Combinations282
Adverse Interactions and Contraindications283
Changing and Weaning Patients off Medications285
Cytochrome P450 (CYP)285
Interactions That Can Affect Dosing285
Algorithms: Possible Future Direction286
Conclusion288
Index291